MCID: LYM027
MIFTS: 54

Lymphopenia

Categories: Blood diseases, Immune diseases

Aliases & Classifications for Lymphopenia

MalaCards integrated aliases for Lymphopenia:

Name: Lymphopenia 12 29 52 42 14 69
Lymphocytopenia 12

Classifications:



External Ids:

Disease Ontology 12 DOID:614
ICD10 33 D72.810
ICD9CM 35 288.51
MeSH 42 D008231
SNOMED-CT 64 48813009
UMLS 69 C0024312

Summaries for Lymphopenia

Disease Ontology : 12 A leukopenia that is the condition of having an abnormally low level of lymphocytes in the blood.

MalaCards based summary : Lymphopenia, also known as lymphocytopenia, is related to lymphoma and silicosis. An important gene associated with Lymphopenia is RAG1 (Recombination Activating 1), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Antibodies and Immunoglobulins have been mentioned in the context of this disorder. Affiliated tissues include t cells, breast and b cells, and related phenotypes are hematopoietic system and endocrine/exocrine gland

Wikipedia : 72 Lymphocytopenia, or lymphopenia, is the condition of having an abnormally low level of lymphocytes in... more...

Related Diseases for Lymphopenia

Diseases related to Lymphopenia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 227)
id Related Disease Score Top Affiliating Genes
1 lymphoma 29.3 FOXP3 IFNG IL2
2 silicosis 28.7 IL2 IL2RG IL7 RAG1
3 malaria 26.7 CD55 FASLG FOXP3 IFNG IL2
4 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 12.1
5 immunodeficiency 13 11.3
6 idiopathic cd4-positive t-lymphocytopenia 11.3
7 immunodeficiency 14 10.8
8 sideroblastic anemia with b-cell immunodeficiency, periodic fevers, and developmental delay 10.8
9 short stature, microcephaly, and endocrine dysfunction 10.8
10 immunodeficiency 17, cd3 gamma deficient 10.8
11 immunodeficiency 50 10.8
12 immunodeficiency, x-linked, with magnesium defect, epstein-barr virus infection and neoplasia 10.8
13 immunodeficiency 22 10.7
14 reticular dysgenesis 10.7
15 immunodeficiency 37 10.7
16 schimke immunoosseous dysplasia 10.7
17 immunodeficiency 40 10.7
18 severe combined immunodeficiency, b cell-negative 10.7
19 immunodeficiency 49 10.7
20 immunodeficiency 8 10.7
21 immunodeficiency 52 10.7
22 neutropenia, severe congenital 4, autosomal recessive 10.7
23 aplasia cutis congenita with intestinal lymphangiectasia 10.7
24 siderosis 10.5 FAS FOXP3
25 alport syndrome-intellectual disability-midface hypoplasia-elliptocytosis syndrome 10.4 FAS IL2RA
26 juvenile sialidosis type 2 10.4 FAS FASLG
27 cd3epsilon deficiency 10.4 IL2RA IL2RG IL7
28 eye accommodation disease 10.3 IFNG IL2RA
29 solid pattern testicular yolk sac tumor 10.3 FOXP3 IL2RG IL7
30 gastrointestinal tuberculosis 10.3 FAS FASLG
31 cogan-reese syndrome 10.3 IL2RA SELL
32 von economo's disease 10.3 FOXP3 IFNG
33 thelaziasis 10.2 IFNG RAG1
34 dysphagia 10.2 IFNG IL2RA RAG1
35 combined cellular and humoral immune defects with granulomas 10.2 FOXP3 IFNG RAG1
36 dieulafoy lesion 10.1 IFNG SELL UNC119
37 systemic lupus erythematosus 10.1
38 lupus erythematosus 10.1
39 hemolytic anemia due to triosephosphate isomerase deficiency 10.1 FOXP3 IL2RA MAGT1 PIK3CD
40 pancreatic somatostatinoma 10.1 FOXP3 IFNG IL7
41 congenital diaphragmatic hernia 10.0 IL2 SELL
42 neutropenia 10.0
43 autoimmune lymphoproliferative syndrome due to ctla4 haploinsuffiency 10.0 FOXP3 IL2RA
44 mental retardation, x-linked, snyder-robinson type 10.0 CD55 CD59
45 influenza 9.9
46 opitz-kaveggia syndrome 9.9 IL2 IL2RG IL7
47 arthritis 9.9
48 autoimmune thyroid disease 4 9.9 FOXP3 IFNG IL2RG RAG1
49 rheumatoid arthritis 9.8
50 pneumonia 9.8

Graphical network of the top 20 diseases related to Lymphopenia:



Diseases related to Lymphopenia

Symptoms & Phenotypes for Lymphopenia

MGI Mouse Phenotypes related to Lymphopenia:

44 (show all 12)
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.34 CD3G CD55 CD59 FAS FASLG FOXP3
2 endocrine/exocrine gland MP:0005379 10.33 IL7 LCK PIK3CD RAG1 SELL CD3G
3 cellular MP:0005384 10.24 CD3G CD59 FAS FASLG FOXP3 IFNG
4 immune system MP:0005387 10.21 IL2RA IL2RG IL7 LCK PIK3CD RAG1
5 homeostasis/metabolism MP:0005376 10.18 CD59 FAS FASLG FOXP3 G6PC3 IFNG
6 cardiovascular system MP:0005385 10.16 IL2 PIK3CD RAG1 SELL UNC119 FAS
7 digestive/alimentary MP:0005381 10.13 FAS FASLG FOXP3 IFNG IL2 IL2RA
8 liver/biliary system MP:0005370 9.87 IFNG IL2 RAG1 SELL FAS FASLG
9 neoplasm MP:0002006 9.8 FAS FASLG IFNG IL2 IL2RG RAG1
10 reproductive system MP:0005389 9.76 IL2RG LCK CD59 FAS FASLG FOXP3
11 respiratory system MP:0005388 9.61 FAS FASLG FOXP3 IFNG IL2 IL2RA
12 vision/eye MP:0005391 9.23 RAG1 UNC119 FAS FASLG FOXP3 IFNG

Drugs & Therapeutics for Lymphopenia

Drugs for Lymphopenia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 172)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1 Antibodies Phase 4,Phase 3,Phase 2,Phase 1
2 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1
3 gamma-Globulins Phase 4,Phase 3
4 Immunoglobulins, Intravenous Phase 4,Phase 3
5 Rho(D) Immune Globulin Phase 4,Phase 3
6
Zinc Approved Phase 3 7440-66-6 32051 23994
7
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
8
Metoclopramide Approved, Investigational Phase 3 364-62-5 4168
9
Selenium Approved, Vet_approved Phase 3 7782-49-2
10 Gastrointestinal Agents Phase 3,Phase 1
11 Peripheral Nervous System Agents Phase 3,Phase 1
12 Protective Agents Phase 3
13 Antiemetics Phase 3,Phase 1
14 Antioxidants Phase 3
15 Autonomic Agents Phase 3
16 Dopamine Agents Phase 3
17 Dopamine Antagonists Phase 3
18 Dopamine D2 Receptor Antagonists Phase 3
19 Micronutrients Phase 3
20 Neurotransmitter Agents Phase 3
21 Trace Elements Phase 3
22 glutamine Nutraceutical Phase 3
23 Whey Protein Nutraceutical Phase 3
24
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
25
Lenalidomide Approved Phase 2 191732-72-6 216326
26
Busulfan Approved, Investigational Phase 1, Phase 2 55-98-1 2478
27
Fludarabine Approved Phase 1, Phase 2 21679-14-1, 75607-67-9 30751
28
Dacarbazine Approved, Investigational Phase 2,Phase 1,Early Phase 1 4342-03-4 5351166
29
Temozolomide Approved, Investigational Phase 2,Phase 1,Early Phase 1 85622-93-1 5394
30
Melphalan Approved Phase 2,Phase 1 148-82-3 4053 460612
31 Thiotepa Approved Phase 2,Phase 1 52-24-4 5453
32
Cyclophosphamide Approved, Investigational Phase 2,Phase 1 50-18-0, 6055-19-2 2907
33
Pembrolizumab Approved Phase 2 1374853-91-4
34
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
35
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
36
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
37
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
38
Lenograstim Approved Phase 2,Phase 1 135968-09-1
39
alemtuzumab Approved, Investigational Phase 2 216503-57-0
40
Mycophenolate mofetil Approved, Investigational Phase 2,Phase 1 128794-94-5 5281078
41
Mycophenolic acid Approved Phase 2,Phase 1 24280-93-1 446541
42
Vidarabine Approved Phase 2,Phase 1 24356-66-9 32326 21704
43
Mechlorethamine Approved Phase 2 51-75-2 4033
44
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 126941
45
Tacrolimus Approved, Investigational Phase 2 104987-11-3 445643 439492
46
Gemcitabine Approved Phase 2 95058-81-4 60750
47
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
48
Epirubicin Approved Phase 2 56420-45-2 41867
49
Exemestane Approved, Investigational Phase 2 107868-30-4 60198
50
Fluorouracil Approved Phase 2 51-21-8 3385

Interventional clinical trials:

(show top 50) (show all 102)

id Name Status NCT ID Phase Drugs
1 A Study to Find Out How Safe and Effective Gammaplex® is in Young People With Primary Immunodeficiency Completed NCT01289847 Phase 4
2 Fumaric Acid Versus Fumaric Acid Plus Narrow Band Type B Ultraviolet (UVB) for Psoriasis Completed NCT01321164 Phase 3 Fumaric acid esters
3 Efficacy, Safety and Pharmacokinetics of Gammaplex in Primary Immunodeficiency Diseases. Completed NCT00278954 Phase 3
4 Rapid Infusion of Immune Globulin Intravenous (Human) In Primary Immunodeficiency Patients Completed NCT00220766 Phase 3 Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified;Dextrose, 5% in Water
5 The CRISIS Prevention Study Terminated NCT00395161 Phase 3 Metoclopramide;Zinc;Selenium
6 GVAX in Advanced Prostate Cancer Patients Made Lymphopenic Unknown status NCT00122005 Phase 1, Phase 2
7 Study Evaluating Impact of IL-7 on CD4 Lymphopenia, Risks of Severe Haematological Toxicity and Tumor Progression in Metastatic Breast Cancer Patients Completed NCT01368107 Phase 2 placebo;interleukin 7;interleukin 7;interleukin 7
8 Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy Completed NCT00815321 Phase 2
9 [F-18] Fluorothymidine PET/CT Imaging for Pelvic Cancers Completed NCT01717391 Phase 2 fluorothymidine F 18
10 Cetuximab and Lenalidomide in Head and Neck Completed NCT01133665 Phase 2 Cetuximab and Lenalidomide
11 Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis Completed NCT02780167 Phase 2 PF-04965842;PF-04965842;PF-04965842;PF-04965842;Placebo
12 Study of Reduced Toxicity Myeloablative Conditioning Regimen for Wiskott-Aldrich Syndrome (WAS) Completed NCT00885833 Phase 1, Phase 2 Fludarabine, Busulfan, Thymoglobulin
13 Unrelated Hematopoietic Stem Cell Transplantation(HSCT) for Genetic Diseases of Blood Cells Completed NCT00730314 Phase 1, Phase 2
14 Evaluation of Pembrolizumab in Lymphopenic Metastatic Breast Cancer Patients Treated With Metronomic Cyclophosphamide Recruiting NCT03139851 Phase 2 Cyclophosphamide 50mg;Pembrolizumab 100 MG in 4 ML Injection
15 EWOC-1 Trial: Carboplatin +/- Paclitaxel in Vulnerable Elderly Patients With Stage III-IV Advanced Ovarian Cancer Recruiting NCT02001272 Phase 2 Paclitaxel + Carboplatin every 3 weeks;Carboplatin monotherapy every 3 weeks;Weekly Paclitaxel and Carboplatin
16 Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata Recruiting NCT02974868 Phase 2 PF-06651600;PF-06700841;Placebo
17 Sequential Cadaveric Lung and Bone Marrow Transplant for Immune Deficiency Diseases Recruiting NCT01852370 Phase 1, Phase 2
18 Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Recruiting NCT02179086 Phase 2 temozolomide
19 A Trial of Plerixafor/G-CSF as Additional Agents for Conditioning Before TCR Alpha/Beta Depleted HSCT in WAS Patients Recruiting NCT03019809 Phase 2
20 Gene Therapy for WAS Follow-up Recruiting NCT02333760 Phase 1, Phase 2
21 Immune Disorder HSCT Protocol Recruiting NCT01821781 Phase 2 Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan
22 Gene Therapy for WAS Recruiting NCT01347346 Phase 1, Phase 2
23 Gene Therapy for Wiskott-Aldrich Syndrome (WAS) Recruiting NCT01347242 Phase 1, Phase 2
24 A Pilot Study of Tumor Cell Vaccine for High-risk Solid Tumor Patients Following Stem Cell Transplantation Active, not recruiting NCT00405327 Phase 2
25 A Study of IL-7 to Restore Absolute Lymphocyte Counts in Sepsis Patients Active, not recruiting NCT02640807 Phase 2 Interleukin-7;Placebo
26 Pyridostigmine as Immunomodulator in People Living With HIV Active, not recruiting NCT03312244 Phase 2 Pyridostigmine Bromide;Placebo
27 Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Active, not recruiting NCT01529827 Phase 2 fludarabine phosphate;melphalan;tacrolimus;mycophenolate mofetil;methotrexate
28 Gene Therapy for Wiskott-Aldrich Syndrome Active, not recruiting NCT01515462 Phase 2
29 Pilot and Feasibility Study of Hematopoietic Stem Cell Gene Transfer for the Wiskott-Aldrich Syndrome Active, not recruiting NCT01410825 Phase 1, Phase 2
30 Thrombocytopenia and Bleeding in Wiskott-Aldrich Syndrome (WAS) Patients Active, not recruiting NCT00909363 Phase 2 Promacta (eltrombopag);Eltrombopag/promacta
31 Interleukin-7 (CYT107) Treatment of Idiopathic CD4 Lymphocytopenia: Expansion of CD4 T Cells (ICICLE) Terminated NCT00839436 Phase 1, Phase 2 CYT107
32 Study of Drug to Reduce Thrombocytopenia in Patients Receiving Chemo for Ovarian, Fallopian Tube or Peritoneal Cancer Terminated NCT00771810 Phase 2 TXA127;TXA127;Placebo
33 A Study of Safety and Clinical Activity of Immunotherapy Plus Chemotherapy in Metastatic Melanoma Patients Terminated NCT00849875 Phase 2 Dacarbazine
34 Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer Terminated NCT01220128 Phase 2 Placebo;Aromatase inhibitor;5-Fluorouracil;Carboplatin AUC;Cyclophosphamide;Docetaxel;Doxorubicin;Epirubicin;Paclitaxel;Trastuzumab
35 Related Hematopoietic Stem Cell Transplantation (HSCT) for Genetic Diseases of Blood Cells Terminated NCT02512679 Phase 2 Cyclophosphamide Dose Level 1;Cyclophosphamide Dose Level 2;Cyclophosphamide Dose Level 3;Cyclophosphamide Dose Level 4
36 Evaluation of Recovery From Drug-Induced Lymphopenia Using Cytomegalovirus-specific T-cell Adoptive Transfer Completed NCT00693095 Phase 1
37 Safety Study of IL-7 in HIV-infected Patients (Inspire) Completed NCT00477321 Phase 1 CYT 107
38 Fludarabine Followed by Vaccine Therapy and White Blood Cell Infusions in Treating Patients With Unresectable or Metastatic Melanoma Completed NCT00091143 Phase 1 fludarabine phosphate
39 A Randomized, Placebo-Controlled, Double-Blind, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986104 in Healthy Male Subjects Completed NCT02211469 Phase 1 BMS-986104;Placebo
40 A Study to Assess the Relative Bioavailability of Different Formulations of GSK2018682, a Sphingosine-1-phosphate Receptor Subtype 1 Agonist, in Healthy Volunteers. Completed NCT01466322 Phase 1 GSK2018682 CD2 Capsule; GSK2018682 CD3 non-micronised Tablet; GSK2018682 CD3 micronised Tablet; GSK2018682 CD3 non-micronised Tablet in fed state
41 Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors Completed NCT00049023 Phase 1
42 Safety Study of IL-7 in Recipients of a Hemopoietic Stem Cell Transplant Peripheral Blood Stem Cell Transplant Completed NCT00684008 Phase 1 CYT107 - Recombinant glycosylated human interleukin 7.;rhIL-7 (CYT107)
43 Study of Dasatinib (BMS-354825) in Patients With Solid Tumors Completed NCT00339144 Phase 1 Dasatinib;Dasatinib;Dasatinib
44 Interleukin-2 Treatment for Wiskott-Aldrich Syndrome Completed NCT00774358 Phase 1 Interleukin-2
45 Haploidentical Hematopoietic Stem Cell Transplantation Patients With Wiskott-Aldrich Syndrome Completed NCT00160355 Phase 1 Fludarabine, Melphalan, Thiotepa
46 Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives Recruiting NCT00001529 Phase 1 G-CSF
47 EGFRvIII CAR T Cells for Newly-Diagnosed GBM Recruiting NCT02664363 Phase 1
48 Prostate Stem Cell Antigen (PSCA)-Specific CAR T Cells In Subjects With Non-Resectable Pancreatic Cancer Recruiting NCT02744287 Phase 1 Rimiducid
49 Dose Finding Study Evaluating Safety and Feasibility in Patients With Relapsed or Refractory Myeloid Neoplasms Recruiting NCT02743611 Phase 1 Rimiducid
50 Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHARKALL Recruiting NCT00881920 Phase 1

Search NIH Clinical Center for Lymphopenia

Cochrane evidence based reviews: lymphopenia

Genetic Tests for Lymphopenia

Genetic tests related to Lymphopenia:

id Genetic test Affiliating Genes
1 Lymphopenia 29

Anatomical Context for Lymphopenia

MalaCards organs/tissues related to Lymphopenia:

39
T Cells, Breast, B Cells, Bone, Bone Marrow, Lung, Kidney

Publications for Lymphopenia

Articles related to Lymphopenia:

(show top 50) (show all 589)
id Title Authors Year
1
Predominance of CD4+ T Cells in T-Cell/Histiocyte-Rich Large B-Cell Lymphoma and Identification of a Subset of Patients With Peripheral B-Cell Lymphopenia. ( 28575178 )
2017
2
Susceptibility to Cryptococcal Meningoencephalitis Associated With Idiopathic CD4(+) Lymphopenia and Secondary Germline or Acquired Defects. ( 28638843 )
2017
3
Dosimetric Predictors of Treatment-related Lymphopenia induced by Palliative Radiotherapy: Predictive Ability of Dose-volume Parameters based on Body Surface Contour. ( 28740459 )
2017
4
Application of pharmacogenomics to investigate adverse drug reactions to the disease-modifying treatments for multiple sclerosis: a case-control study protocol for dimethyl fumarate-induced lymphopenia. ( 28576902 )
2017
5
T-Cell Lymphopenia Detected by Newborn Screening in Two Siblings with an Xq13.1 Duplication. ( 28770187 )
2017
6
Profound T-cell lymphopenia associated with prenatal exposure to purine antagonists detected by TREC newborn screening. ( 28065337 )
2017
7
First Report of CD4 Lymphopenia and Defective Neutrophil Functions in a Patient with Amebiasis Associated with CMV Reactivation and Severe Bacterial and Fungal Infections. ( 28243230 )
2017
8
Depletion-Resistant CD4 T Cells Enhance Thymopoiesis During Lymphopenia. ( 28397358 )
2017
9
Lymphopenia and CD4+/CD8+ Cell Reduction under Fumaric Acid Esters. ( 28954274 )
2017
10
Approach to Fingolimod-Induced Lymphopenia in Multiple Sclerosis Patients: Do We Have a Roadmap? ( 28543950 )
2017
11
Systemic inflammatory response syndrome-related lymphopenia is associated with adenosine A1 receptor dysfunction. ( 28495790 )
2017
12
Radiation-related lymphopenia is associated with spleen irradiation dose during radiotherapy in patients with hepatocellular carcinoma. ( 28558844 )
2017
13
Idiopathic T cell lymphopenia identified in New York State Newborn Screening. ( 28694137 )
2017
14
Dysplasia of Granulocytes in a Patient with HPV Disease, Recurrent Infections, and B Lymphopenia: A Novel Variant of WHIM Syndrome? ( 28512628 )
2017
15
Large Deletion of MAGT1 Gene in a Patient with Classic Kaposi Sarcoma, CD4 Lymphopenia, and EBV Infection. ( 27770395 )
2017
16
Immunologic Effects of Maraviroc in HIV-Infected Patients with Severe CD4 Lymphopenia Starting Antiretroviral Therapy: A Sub-Study of the CADIRIS Trial. ( 28736763 )
2017
17
Systemic Intravenous Adoptive Transfer of Autologous Lymphokine-activated I+I^ T-Cells Improves Temozolomide-induced Lymphopenia in Patients with Glioma. ( 28668896 )
2017
18
Baseline lymphopenia should not be used as exclusion criteria in early clinical trials investigating immune checkpointA blockers (PD-1/PD-L1 inhibitors). ( 28826073 )
2017
19
New FTY720-docetaxel nanoparticle therapy overcomes FTY720-induced lymphopenia and inhibits metastatic breast tumour growth. ( 28695300 )
2017
20
The Prognostic Value of Treatment-Related Lymphopenia in Nasopharyngeal Carcinoma Patients. ( 28392551 )
2017
21
Intestinal microbiota link lymphopenia to murine autoimmunity via PD-1(+)CXCR5(-/dim) B-helper T cell induction. ( 28443628 )
2017
22
What Does Screening Newborns for T-Cell Lymphopenia Find? ( 28888255 )
2017
23
Lymphocytosis and Lymphopenia Induced by Imported Infectious Diseases: A Controlled Cross-Sectional Study of 17,229 Diseased German Travelers Returning from the Tropics and Subtropics. ( 27068397 )
2016
24
Immune Control Despite Protracted Lymphopenia After Chemoradiation in an Elite Controller. ( 26949716 )
2016
25
Distinct roles of T-cell lymphopenia and the microbial flora for gastrointestinal and CNS autoimmunity. ( 26740263 )
2016
26
Risk Factors and Clinical Significance of Lymphopenia in Survivors of the Fontan Procedure for Single-Ventricle Congenital Cardiac Disease. ( 26897303 )
2016
27
Lymphopenia as a predictor of sarcoidosis in patients with uveitis. ( 26729767 )
2016
28
FTY720-Induced Lymphopenia does not Aggravate Mortality in a Murine Model of Polymicrobial Abdominal Sepsis. ( 27559700 )
2016
29
IL-15 signaling promotes adoptive effector T-cell survival and memory formation in irradiation-induced lymphopenia. ( 27158441 )
2016
30
JC virus granule cell neuronopathy in the setting of chronic lymphopenia treated with recombinant interleukin-7. ( 27421731 )
2016
31
Lymphopenia can be a useful biomarker of adverse events related to vemurafenib. ( 26810349 )
2016
32
Pretreatment lymphopenia is an easily detectable predictive and prognostic marker in patients with metastatic esophagus squamous cell carcinoma receiving first-line chemotherapy. ( 26814381 )
2016
33
Association between treatment-related lymphopenia and overall survival in elderly patients with newly diagnosed glioblastoma. ( 26725885 )
2016
34
CD4 T Helper Cells Instruct Lymphopenia-Induced Memory-Like CD8 T Cells for Control of Acute LCMV Infection. ( 28066432 )
2016
35
Lymphopenia at 4 Days Postoperatively Is the Most Significant Laboratory Marker for Early Detection of Surgical Site Infection Following Posterior Lumbar Instrumentation Surgery. ( 27994779 )
2016
36
Lymphopenia in treatment-naive relapsing multiple sclerosis. ( 27559542 )
2016
37
CD4 T Cell Help via B Cells Is Required for Lymphopenia-Induced CD8 T Cell Proliferation. ( 26912319 )
2016
38
Patterns of Radiation-Associated Lymphopenia in Children with Cancer. ( 26745229 )
2016
39
PML during dimethyl fumarate treatment of multiple sclerosis: How does lymphopenia matter? ( 27343070 )
2016
40
Component of Caramel Food Coloring, THI, Causes Lymphopenia Indirectly via a Key Metabolic Intermediate. ( 27185637 )
2016
41
Pretreatment Lymphopenia, Poor Performance Status, and Early Courses of Therapy Are Risk Factors for Severe Bacterial Infection in Patients with Multiple Myeloma during Treatment with Bortezomib-based Regimens. ( 27051233 )
2016
42
Cutaneous Extranodal NK/T Cell Lymphoma Mimicking Cellulitis in a HIV Positive Patient without Lymphopenia. ( 28035700 )
2016
43
Worsening of Lymphopenia during Apremilast Treatment. ( 27920684 )
2016
44
TGN1412 Induces Lymphopenia and Human Cytokine Release in a Humanized Mouse Model. ( 26959227 )
2016
45
A hypofractionated radiation regimen avoids the lymphopenia associated with neoadjuvant chemoradiation therapy of borderline resectable and locally advanced pancreatic adenocarcinoma. ( 27532020 )
2016
46
Lymphopenia and autoimmunity: A double-edged sword. ( 27343993 )
2016
47
Profound lymphopenia is associated with a lower risk of hepatic cytolysis during antithymocyte globulin administration. ( 26799506 )
2016
48
Lymphopenia, Infectious Complications, and Outcome in Spontaneous Intracerebral Hemorrhage. ( 28004330 )
2016
49
Idiopathic CD4 Lymphopenia: Severe CD4 Lymphopenia in the Absence of Human Immunodeficiency Virus Infection. ( 28471626 )
2016
50
Apoptosis-induced lymphopenia in sepsis and other severe injuries. ( 27812767 )
2016

Variations for Lymphopenia

Expression for Lymphopenia

Search GEO for disease gene expression data for Lymphopenia.

Pathways for Lymphopenia

Pathways related to Lymphopenia according to GeneCards Suite gene sharing:

(show all 41)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
14.01 CD3G CD55 CD59 FASLG IFNG IL2
2
Show member pathways
13.62 CD3G FAS FASLG IFNG IL2 IL2RA
3
Show member pathways
13.41 CD3G FAS FASLG IL2 IL2RA IL2RG
4
Show member pathways
13.39 FASLG IFNG IL2 IL2RA IL2RG IL7
5
Show member pathways
12.89 CD3G FAS FASLG IFNG IL2 PIK3CD
6
Show member pathways
12.82 CD3G CD55 FAS FASLG FOXP3 IFNG
7
Show member pathways
12.76 IL2 IL2RA IL2RG IL7 PIK3CD
8
Show member pathways
12.75 CD3G FAS FASLG IFNG IL2 IL2RA
9 12.69 FAS FASLG G6PC3 IL2 IL2RA IL2RG
10
Show member pathways
12.66 CD3G IFNG IL2 IL2RA LCK PIK3CD
11
Show member pathways
12.61 CD3G FOXP3 IFNG IL2 IL2RA IL2RG
12
Show member pathways
12.57 FAS FASLG IFNG IL2 LCK PIK3CD
13
Show member pathways
12.47 CD3G FAS IFNG IL2 LCK PIK3CD
14 12.46 CD3G IL2 IL2RA IL2RG LCK PIK3CD
15
Show member pathways
12.42 CD3G IL2 IL2RA IL2RG LCK
16 12.42 FAS FASLG FOXP3 IFNG IL2 IL2RA
17
Show member pathways
12.21 IFNG IL2 IL2RA IL2RG IL7 PIK3CD
18
Show member pathways
12.2 IL2 IL2RA IL2RG LCK PIK3CD
19
Show member pathways
12.12 CD3G IL2 LCK PIK3CD
20
Show member pathways
12.12 IFNG IL2 IL2RA IL2RG LCK
21
Show member pathways
12.1 FASLG G6PC3 PIK3CD RAG1
22
Show member pathways
12.01 IL2 IL2RA IL2RG LCK PIK3CD
23 11.98 CD59 IFNG IL2 IL2RA IL7 SELL
24 11.93 CD3G CD55 CD59 IL2RA IL7
25 11.84 IFNG IL2 IL2RA IL7
26
Show member pathways
11.79 FASLG FOXP3 IFNG IL2 IL2RA
27 11.74 IFNG IL2 SELL
28 11.72 FAS FASLG PIK3CD
29 11.61 FAS FASLG IFNG IL2
30
Show member pathways
11.56 FASLG FOXP3 IL2 IL2RA IL2RG LCK
31
Show member pathways
11.55 CD3G FASLG IFNG IL2 IL2RA IL2RG
32
Show member pathways
11.49 IL2RA IL2RG IL7
33 11.47 FOXP3 IFNG IL2 IL2RA IL2RG
34
Show member pathways
11.42 CD3G FASLG IFNG IL2 IL2RA IL2RG
35 11.4 IL2RG LCK RAG1
36 11.37 FAS FASLG IFNG
37 11.3 IFNG IL2 IL7
38 11.28 CD3G IFNG IL2 IL2RA
39 11.28 IFNG IL2 IL2RA IL2RG LCK
40 11.27 IL2RG IL7 RAG1
41
Show member pathways
10.77 FAS FASLG FOXP3 IFNG IL2 IL2RA

GO Terms for Lymphopenia

Cellular components related to Lymphopenia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.8 CD3G CD55 FAS FASLG IL2RG MAGT1
2 membrane raft GO:0045121 9.46 CD55 FAS FASLG LCK
3 cell surface GO:0009986 9.43 CD55 CD59 FAS FASLG IL2RA SELL
4 external side of plasma membrane GO:0009897 9.1 FAS FASLG IFNG IL2RA IL2RG SELL

Biological processes related to Lymphopenia according to GeneCards Suite gene sharing:

(show all 26)
id Name GO ID Score Top Affiliating Genes
1 cell surface receptor signaling pathway GO:0007166 9.92 CD3G CD59 IFNG IL2RA
2 adaptive immune response GO:0002250 9.87 IFNG IL2 PIK3CD RAG1
3 negative regulation of inflammatory response GO:0050728 9.78 FOXP3 IL2 IL2RA
4 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.77 FAS FASLG LCK
5 T cell receptor signaling pathway GO:0050852 9.77 CD3G FOXP3 IFNG LCK PIK3CD
6 T cell activation GO:0042110 9.72 CD3G FOXP3 PIK3CD
7 positive regulation of T cell proliferation GO:0042102 9.71 CD59 IFNG IL2 IL2RA
8 extrinsic apoptotic signaling pathway GO:0097191 9.7 FAS FASLG IFNG
9 T cell differentiation GO:0030217 9.65 IL2 LCK PIK3CD
10 regulation of extrinsic apoptotic signaling pathway via death domain receptors GO:1902041 9.63 FAS FASLG
11 negative regulation of immune response GO:0050777 9.62 FOXP3 IL2RA
12 activation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway GO:0097296 9.61 FAS FASLG
13 negative regulation of interleukin-17 production GO:0032700 9.59 FOXP3 IFNG
14 positive regulation of regulatory T cell differentiation GO:0045591 9.58 FOXP3 IL2
15 positive regulation of isotype switching to IgG isotypes GO:0048304 9.58 IFNG IL2
16 necroptotic signaling pathway GO:0097527 9.56 FAS FASLG
17 T cell homeostasis GO:0043029 9.56 FAS FOXP3 IL2RA RAG1
18 immune response GO:0006955 9.56 FAS FASLG IFNG IL2 IL2RA IL2RG
19 activation-induced cell death of T cells GO:0006924 9.54 FAS IL2RA
20 negative regulation of T-helper 17 cell differentiation GO:2000320 9.51 FOXP3 IL2
21 negative regulation of lymphocyte proliferation GO:0050672 9.5 FOXP3 IL2 IL2RA
22 interleukin-2-mediated signaling pathway GO:0038110 9.49 IL2RA IL2RG
23 regulation of T cell homeostatic proliferation GO:0046013 9.46 IL2 IL2RA
24 inflammatory cell apoptotic process GO:0006925 9.33 FAS FASLG IFNG
25 interleukin-7-mediated signaling pathway GO:0038111 9.13 IL2RG
26 positive regulation of T cell differentiation GO:0045582 8.92 IL2 IL2RA IL7 RAG1

Molecular functions related to Lymphopenia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.62 FASLG IFNG IL2 IL7
2 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.54 IL2 IL2RA IL2RG
3 T cell receptor binding GO:0042608 9.26 CD3G LCK
4 glycosphingolipid binding GO:0043208 9.16 IL2 SELL
5 interleukin-2 binding GO:0019976 8.96 IL2RA IL2RG
6 interleukin-2 receptor activity GO:0004911 8.62 IL2RA IL2RG

Sources for Lymphopenia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....